Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration

Chest

Volumn 132, Issue 2, 2007, Pages 597-602

  Nakajima, Takahiro ^a   Yasufuku, Kazuhiro ^a   Suzuki, Makoto ^a   Hiroshima, Kenzo ^a   Kubo, Rieko ^a   Mohammed, Sherif ^a   Miyagi, Yohei ^b   Matsukuma, Shoichi ^b   Sekine, Yasuo ^a   Fujisawa, Takehiko ^a  

^a CHIBA UNIVERSITY   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

Author keywords

Biopsy; Bronchoscopy; Genetics; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PARAFFIN; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BRONCHUS; CLINICAL ARTICLE; DNA EXTRACTION; EMBEDDING; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; NEEDLE BIOPSY; POINT MUTATION; PRIORITY JOURNAL; TREATMENT RESPONSE; ULTRASOUND;

EID: 34548020773     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0095     Document Type: Article

References (21)

1. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005; 10(suppl):1-10
2. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2006; 23:2513-2520
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500
5. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311
6. Yasufuku K, Chiyo M, Sekine Y, et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest 2004; 126:122-128
7. Yasufuku K, Chiyo M, Koh E, et al. Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer. Lung Cancer 2005; 50:347-354
8. Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006; 130:710-718
9. Herth FJ, Ernst A, Eberhardt R, et al. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically normal mediastinum. Eur Respir J 2006; 28:910-914
10. Herth FJ, Eberhardt R, Vilmann P, et al. Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes. Thorax 2006; 61:795-798
11. Suzuki M, Shigematsu H, Hiroshima K, et al. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 2005; 36:1127-1134
12. Matsukuma S, Yoshihara M, Kasai F, et al. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn 2006; 8:504-512
13. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutations and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786-792
14. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2007; 2:e73
15. Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006; 118:963-969
16. Fujita S, Mio T, Sonobe M, et al. Accuracy of epidermal growth factor receptor mutation analysis on the basis of small biopsy specimens in patients with nonsmall cell lung cancer. Int J Cancer 2006; 119:1751-1752
17. Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006; 12:3915-3921
18. Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006; 97:642-648
19. Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006; 12:43-48
20. Janne PA, Borras AM, Kuang Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 2006; 12:751-758
21. Yatabe Y, Hida T, Horio Y, et al. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006; 8:335-341